[Clinical analysis of lumbar spondylosis].

S. Zarski,W. Leo,H. Pawlik-Dobrowolska,T. Styczyński,H. Garwolińska,A. Filipowicz-Sosnowska,M. Sadowska-Wróblewska

Rheumatology

Abstract:

What problem does this paper attempt to address?

Progress of research on PD-1/PD-L1 in leukemia

Huizhen Cao,Tianyu Wu,Xue Zhou,Shuyang Xie,Hongfang Sun,Yunxiao Sun,Youjie Li

DOI: https://doi.org/10.3389/fimmu.2023.1265299

IF: 7.3

2023-09-26

Frontiers in Immunology

Abstract:Leukemia cells prevent immune system from clearing tumor cells by inducing the immunosuppression of the bone marrow (BM) microenvironment. In recent years, further understanding of the BM microenvironment and immune landscape of leukemia has resulted in the introduction of several immunotherapies, including checkpoint inhibitors, T-cell engager, antibody drug conjugates, and cellular therapies in clinical trials. Among them, the programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) axis is a significant checkpoint for controlling immune responses, the PD-1 receptor on tumor-infiltrating T cells is bound by PD-L1 on leukemia cells. Consequently, the activation of tumor reactive T cells is inhibited and their apoptosis is promoted, preventing the rejection of the tumor by immune system and thus resulting in the occurrence of immune tolerance. The PD-1/PD-L1 axis serves as a significant mechanism by which tumor cells evade immune surveillance, and PD-1/PD-L1 checkpoint inhibitors have been approved for the treatment of lymphomas and varieties of solid tumors. However, the development of drugs targeting PD-1/PD-L1 in leukemia remains in the clinical-trial stage. In this review, we tally up the basic research and clinical trials on PD-1/PD-L1 inhibitors in leukemia, as well as discuss the relevant toxicity and impacts of PD-1/PD-L1 on other immunotherapies such as hematopoietic stem cell transplantation, bi-specific T-cell engager, chimeric antigen receptor T-cell immunotherapy.

immunology
Acute Myeloid Leukemia Cell-Intrinsic PD-1 Functions Promoting Leukemia Development by Recruiting SHP2

Shanshan Suo,Le Xuan Truong Nguyen,Fenglin Li,Dandan Zhao,Junjing Qiao,Chen Liang,Dinh Hoa Hoang,Fang Chen,Ivan Rodriguez,Lucy Ghoda,Tinisha McDonald,Ling Li,Bin Amber Zhang,Jie Jin,Guido Marcucci

DOI: https://doi.org/10.1182/blood-2021-154467

IF: 20.3

2021-01-01

Blood

Abstract:Acute myeloid leukemia (AML) is a devastating hematopoietic malignancy. With current therapies, only approximately 30% of patients achieve long-term survival. Therefore, novel, more active and less toxic treatments are urgently needed. Programmed death-1 (PD-1) is a cell surface receptor that functions as a T cell checkpoint and plays a central role in regulating T cell exhaustion. Binding of PD-1 to its ligand, programmed death-ligand 1 (PD-L1), activates downstream signaling pathways and inhibits T cell activation. Abnormally high PD-L1 expression on tumor cells and antigen-presenting cells in the tumor microenvironment mediates tumor immune escape, and PD-1/PD-L1 immune checkpoint blockade has showed promising results in cancer patients. Recently, PD-1 expressed on melanoma cells was also shown to play a pivotal role in tumor growth. To date, in AML, the function of PD-1 has been mainly studied in the host T cells, while little is known regarding the role of PD-1 in AML cells. Herein, we examined the level and role of PD-1 in AML cells using AML murine model and patient samples.
Targeting PD-1/PD-L1 pathway in myelodysplastic syndromes and acute myeloid leukemia

Xingcheng Yang,Ling Ma,Xiaoying Zhang,Liang Huang,Jia Wei

DOI: https://doi.org/10.1186/s40164-022-00263-4

2022-03-02

Experimental Hematology and Oncology

Abstract:Abstract Myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) are clonal hematopoietic stem cell diseases arising from the bone marrow (BM), and approximately 30% of MDS eventually progress to AML, associated with increasingly aggressive neoplastic hematopoietic clones and poor survival. Dysregulated immune microenvironment has been recognized as a key pathogenic driver of MDS and AML, causing high rate of intramedullary apoptosis in lower-risk MDS to immunosuppression in higher-risk MDS and AML. Immune checkpoint molecules, including programmed cell death-1 (PD-1) and programmed cell death ligand-1 (PD-L1), play important roles in oncogenesis by maintaining an immunosuppressive tumor microenvironment. Recently, both molecules have been examined in MDS and AML. Abnormal inflammatory signaling, genetic and/or epigenetic alterations, interactions between cells, and treatment of patients all have been involved in dysregulating PD-1/PD-L1 signaling in these two diseases. Furthermore, with the PD-1/PD-L1 pathway activated in immune microenvironment, the milieu of BM shift to immunosuppressive, contributing to a clonal evolution of blasts. Nevertheless, numerous preclinical studies have suggested a potential response of patients to PD-1/PD-L1 blocker. Current clinical trials employing these drugs in MDS and AML have reported mixed clinical responses. In this paper, we focus on the recent preclinical advances of the PD-1/PD-L1 signaling in MDS and AML, and available and ongoing outcomes of PD-1/PD-L1 inhibitor in patients. We also discuss the novel PD-1/PD-L1 blocker-based immunotherapeutic strategies and challenges, including identifying reliable biomarkers, determining settings, and exploring optimal combination therapies.

oncology,hematology
Strategies targeting PD-L1 expression and associated opportunities for cancer combination therapy

Shuangneng Yin,Zhaojun Chen,Dugang Chen,Dan Yan

DOI: https://doi.org/10.7150/thno.80091

IF: 11.6

2023-03-05

Theranostics

Abstract:Immunotherapy has achieved great success recently and opened a new avenue for anti-tumor treatment. Programmed cell death 1/programmed cell death ligand 1 (PD-1/PD-L1) are typical immune checkpoints that transmit coinhibitory signals, muting the host immunity. Monoclonal antibodies that block PD-1/PD-L1 axis have benefited many patients with different tumor diseases. However, the objective response rate is still unsatisfactory. In this review, we summarize three strategies targeting PD-L1 based on different forms of PD-L1 and various regulating mechanisms to enhance the therapeutic effect, including blockade of the interaction between PD-L1 and PD-1, downregulation of PD-L1 expression and degradation of mature PD-L1. Thereinto, we describe a variety of materials have been designed to target PD-L1, including antibodies, nanoparticle, peptide, aptamer, RNA, and small molecule. Additionally, we list the drugs with PD-L1 regulation capacity used in clinical and ongoing studies to explore other alternatives for targeting PD-L1 besides anti-PD-L1 monoclonal antibodies. Moreover, we discuss associated opportunities for cancer combination therapy with other modalities such as chemotherapy, radiotherapy, photodynamic therapy (PDT) and photothermal therapy (PTT), as these conventional or emerging modalities are capable of increasing the immune response of tumor cells by altering the tumor microenvironment (TME), and would display synergistic effect. At last, we give a brief summary and outlook regarding the research status and future prospect of immunotherapy.
Emerging therapeutic frontiers in cancer: insights into posttranslational modifications of PD-1/PD-L1 and regulatory pathways

Rong Wang,Shiwei He,Jun Long,Yian Wang,Xianjie Jiang,Mingfen Chen,Jie Wang

DOI: https://doi.org/10.1186/s40164-024-00515-5

2024-04-26

Experimental Hematology and Oncology

Abstract:The interaction between programmed cell death ligand 1 (PD-L1), which is expressed on the surface of tumor cells, and programmed cell death 1 (PD-1), which is expressed on T cells, impedes the effective activation of tumor antigen-specific T cells, resulting in the evasion of tumor cells from immune-mediated killing. Blocking the PD-1/PD-L1 signaling pathway has been shown to be effective in preventing tumor immune evasion. PD-1/PD-L1 blocking antibodies have garnered significant attention in recent years within the field of tumor treatments, given the aforementioned mechanism. Furthermore, clinical research has substantiated the efficacy and safety of this immunotherapy across various tumors, offering renewed optimism for patients. However, challenges persist in anti-PD-1/PD-L1 therapies, marked by limited indications and the emergence of drug resistance. Consequently, identifying additional regulatory pathways and molecules associated with PD-1/PD-L1 and implementing judicious combined treatments are imperative for addressing the intricacies of tumor immune mechanisms. This review briefly outlines the structure of the PD-1/PD-L1 molecule, emphasizing the posttranslational modification regulatory mechanisms and related targets. Additionally, a comprehensive overview on the clinical research landscape concerning PD-1/PD-L1 post-translational modifications combined with PD-1/PD-L1 blocking antibodies to enhance outcomes for a broader spectrum of patients is presented based on foundational research.

oncology,hematology
The progress and challenge of anti-PD-1/PD-L1 immunotherapy in treating non-small cell lung cancer

Jingjing Qu,Quanhui Mei,Li Liu,Tianli Cheng,Peng Wang,Lijun Chen,Jianying Zhou

DOI: https://doi.org/10.1177/1758835921992968

2021-01-01

Therapeutic Advances in Medical Oncology

Abstract:The use of programmed cell-death protein 1 (PD-1)/programmed cell-death ligand 1 (PD-L1) inhibitors is the standard therapy for the first-line or second-line treatment of patients with non-small-cell lung cancer (NSCLC). In contrast to current traditional treatments such as chemotherapy or radiotherapy, anti-PD-1 and anti-PD-L1 treatments can directly attenuate tumour-mediated exhaustion and effectively modulate the host anti-tumour immune response in vivo. In addition, compared with traditional therapy, PD-1/PD-L1 inhibitor monotherapy can significantly prolong survival without obvious side effects in the treatment of advanced NSCLC. Ideally, several biomarkers could be used to monitor the safety and effectiveness of anti-PD-1 and anti-PD-L1 treatments; however, the current lack of optimal prognostic markers remains a widespread limitation and challenge for further clinical applications, as does the possibility of immune-related adverse events and drug resistance. In this review, we aimed to summarise the latest progress in anti-PD-1/anti-PD-L1 treatment of advanced NSCLC, worldwide, including in China. An exploration of underlying biomarker identification and future challenges will be discussed in this article to facilitate translational studies in cancer immunotherapy.

oncology
Recent progress, perspectives, and issues of engineered PD-L1 regulation nano-system to better cure tumor: A review

Zaigang Zhou,Haoxiang Wang,Jie Li,Xin Jiang,Zhangping Li,Jianliang Shen

DOI: https://doi.org/10.1016/j.ijbiomac.2023.127911

IF: 8.2

2023-11-09

International Journal of Biological Macromolecules

Abstract:Currently, immune checkpoint blockade (ICB) therapies that target the programmed cell death ligand-1 (PD-L1) have been used as revolutionary cancer treatments in the clinic. Apart from restoring the antitumor response of cytotoxic T cells by blocking the interaction between PD-L1 on tumor cells and programmed cell death-1 (PD-1) on T cells, PD-L1 proteins were also newly revealed to possess the capacity to accelerate DNA damage repair (DDR) and enhance tumor growth through multiple mechanisms, leading to the impaired efficacy of tumor therapies. Nevertheless, current free anti-PD-1/PD-L1 therapy still suffered from poor therapeutic outcomes in most solid tumors due to the non-selective tumor accumulation, ineludible severe cytotoxic effects, as well as the common occurrence of immune resistance. Recently, nanoparticles with efficient tumor-targeting capacity, tumor-responsive prosperity, and versatility for combination therapy were identified as new avenues for PD-L1 targeting cancer immunotherapies. In this review, we first summarized the multiple functions of PD-L1 protein in promoting tumor growth, accelerating DDR, as well as depressing immunotherapy efficacy. Following this, the effects and mechanisms of current clinically widespread tumor therapies on tumor PD-L1 expression were discussed. Then, we reviewed the recent advances in nanoparticles for anti-PD-L1 therapy via using PD-L1 antibodies, small interfering RNA (siRNA), microRNA (miRNA), clustered, regularly interspaced, short palindromic repeats (CRISPR), peptide, and small molecular drugs. At last, we discussed the challenges and perspectives to promote the clinical application of nanoparticles-based PD-L1-targeting therapy.

polymer science,biochemistry & molecular biology,chemistry, applied
[Prevention of neuroses by timely heeding of complaints].

K. Leonhard

Abstract:
Various Uses of PD1/PD-L1 Inhibitor in Oncology: Opportunities and Challenges

Zhitao Li,Guoqiang Sun,Guangshun Sun,Ye Cheng,Liangliang Wu,Qian Wang,Chengyu Lv,Yichan Zhou,Yongxiang Xia,Weiwei Tang

DOI: https://doi.org/10.3389/fonc.2021.771335

IF: 4.7

2021-11-17

Frontiers in Oncology

Abstract:The occurrence and development of cancer are closely related to the immune escape of tumor cells and immune tolerance. Unlike previous surgical, chemotherapy, radiotherapy and targeted therapy, tumor immunotherapy is a therapeutic strategy that uses various means to stimulate and enhance the immune function of the body, and ultimately achieves the goal of controlling tumor cells.With the in-depth understanding of tumor immune escape mechanism and tumor microenvironment, and the in-depth study of tumor immunotherapy, immune checkpoint inhibitors represented by Programmed Death 1/Programmed cell Death-Ligand 1(PD-1/PD-L1) inhibitors are becoming increasingly significant in cancer medication treatment. employ a variety of ways to avoid detection by the immune system, a single strategy is not more effective in overcoming tumor immune evasion and metastasis. Combining different immune agents or other drugs can effectively address situations where immunotherapy is not efficacious, thereby increasing the chances of success and alternative access to alternative immunotherapy. Immune combination therapies for cancer have become a hot topic in cancer treatment today. In this paper, several combination therapeutic modalities of PD1/PD-L1 inhibitors are systematically reviewed. Finally, an analysis and outlook are provided in the context of the recent advances in combination therapy with PD1/PD-L1 inhibitors and the pressing issues in this field.

oncology
The role of PD-1/PD-L1 and application of immune-checkpoint inhibitors in human cancers

Qing Tang,Yun Chen,Xiaojuan Li,Shunqin Long,Yao Shi,Yaya Yu,Wanyin Wu,Ling Han,Sumei Wang

DOI: https://doi.org/10.3389/fimmu.2022.964442

IF: 7.3

2022-09-13

Frontiers in Immunology

Abstract:Programmed cell death protein-1 (PD-1) is a checkpoint receptor expressed on the surface of various immune cells. PD-L1, the natural receptor for PD-1, is mainly expressed in tumor cells. Studies have indicated that PD-1 and PD-L1 are closely associated with the progression of human cancers and are promising biomarkers for cancer therapy. Moreover, the interaction of PD-1 and PD-L1 is one of the important mechanism by which human tumors generate immune escape. This article provides a review on the role of PD-L1/PD-1, mechanisms of immune response and resistance, as well as immune-related adverse events in the treatment of anti-PD-1/PD-L1 immunotherapy in human cancers. Moreover, we summarized a large number of clinical trials to successfully reveal that PD-1/PD-L1 Immune-checkpoint inhibitors have manifested promising therapeutic effects, which have been evaluated from different perspectives, including overall survival, objective effective rate and medium progression-free survival. Finally, we pointed out the current problems faced by PD-1/PD-L1 Immune-checkpoint inhibitors and its future prospects. Although PD-1/PD-L1 immune checkpoint inhibitors have been widely used in the treatment of human cancers, tough challenges still remain. Combination therapy and predictive models based on integrated biomarker determination theory may be the future directions for the application of PD-1/PD-L1 Immune-checkpoint inhibitors in treating human cancers.

immunology
PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations

Yongshuai Jiang,Ming Chen,Hong Nie,Yuanyang Yuan

DOI: https://doi.org/10.1080/21645515.2019.1571892

2019-03-19

Abstract:Programmed death-1 (PD-1) is a cell surface receptor that functions as a T cell checkpoint and plays a central role in regulating T cell exhaustion. Binding of PD-1 to its ligand, programmed death-ligand 1 (PD-L1), activates downstream signaling pathways and inhibits T cell activation. Moreover abnormally high PD-L1 expression on tumor cells and antigen-presenting cells in the tumor microenvironment mediates tumor immune escape, and the development of anti-PD-1/PD-L1 antibodies has recently become a hot topic in cancer immunotherapy. Here, we review the structure of PD-1 and PD-L1, the function of the PD-1/PD-L1 signaling pathway, the application of PD-1 or PD-L1 monoclonal antibodies and future directions for anti-PD-1/PD-L1 antibodies with combination therapies. Cancer immunotherapy using PD-1/PD-L1 immune checkpoint blockade may require more studies, and this approach may be curative for patients with many types of cancer in the future.

immunology,biotechnology & applied microbiology
PD-L1: From cancer immunotherapy to therapeutic implications in multiple disorders

Daeun Lee,Minjeong Cho,Eunseo Kim,Youngbin Seo,Jong-Ho Cha

DOI: https://doi.org/10.1016/j.ymthe.2024.09.026

2024-09-28

Abstract:The PD-L1/PD-1 signaling pathway is the gold standard for cancer immunotherapy. Therapeutic antibodies targeting PD-1, such as nivolumab (Opdivo) and pembrolizumab (Keytruda), and PD-L1, including atezolizumab (Tecentriq), durvalumab (Imfinzi), and avelumab (Bavencio) have received Food and Drug Administration approval and are currently being used to treat various cancers. Traditionally, PD-L1 is known as an immune checkpoint protein that binds to the PD-1 receptor on its surface to inhibit the activity of T cells, which are the primary effector cells in antitumor immunity. However, it also plays a role in cancer progression, which goes beyond traditional understanding. Here, we highlight the multifaceted mechanisms of action of PD-L1 in cancer cell proliferation, transcriptional regulation, and systemic immune suppression. Moreover, we consider the potential role of PD-L1 in the development and pathogenesis of diseases other than cancer, explore PD-L1-focused therapeutic approaches for these diseases, and assess their clinical relevance. Through this review, we hope to provide deeper insights into the PD-L1/PD-1 signaling pathway and present a broad perspective on potential therapeutic approaches for cancer and other diseases.
PD-1/PD-L1 pathway: current researches in cancer.

Dandan Liu,Yanyan Han,Lianhong Li

2020-03-01

American journal of cancer research

Abstract:Cancer immunotherapy has been accompanied by promising results over the past few years. Programmed Cell Death Protein 1 (PD-1) plays a vital role in inhibiting immune responses and promoting self-tolerance through modulating the activity of T-cells, activating apoptosis of antigen-specific T cells and inhibiting apoptosis of regulatory T cells. Programmed Cell Death Ligand 1 (PD-L1) is a trans-membrane protein that is considered to be a co-inhibitory factor of the immune response, it can combine with PD-1 to reduce the proliferation of PD-1 positive cells, inhibit their cytokine secretion and induce apoptosis. PD-L1 also plays an important role in various malignancies where it can attenuate the host immune response to tumor cells. Based on these perspectives, PD-1/PD-L1 axis is responsible for cancer immune escape and makes a huge effect on cancer therapy. This review is aimed to summarize the role of PD-1 and PD-L1 in cancer, looking forward to improve the therapy of cancer.

Medicine
PD-1 regulation in immune homeostasis and immunotherapy

Minling Gao,Jie Shi,Xiangling Xiao,Yingmeng Yao,Xu Chen,Bin Wang,Jinfang Zhang

DOI: https://doi.org/10.1016/j.canlet.2024.216726

IF: 9.756

2024-02-24

Cancer Letters

Abstract:Harnessing the programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) axis is pivotal in autoimmunity and cancer immunotherapy. PD-1 receptors on immune cells engage with one of its ligands, PD-L1 or PD-L2, expressed on antigen-presenting cells or tumor cells, driving T-cell dysfunction and tumor immune escape. Thus, targeting PD-1/PD-L1 revitalizes cytotoxic T cells for cancer elimination. However, a majority of cancer patients don't respond to PD-1/PD-L1 blockade, and the underlying mechanisms remain partially understood. Recent studies have revealed that PD-1 expression levels or modifications impact the effectiveness of anti -PD-1/PD-L1 treatments. Therefore, understanding the molecular mechanisms governing PD-1 expression and modifications is crucial for innovating therapeutic strategies to enhance the efficacy of PD-1/PD-L1 inhibition. This article presents a comprehensive overview of advancements in PD-1 regulation and highlights their potential in modulating immune homeostasis and cancer immunotherapy, aiming to refine clinical outcomes.

oncology
Extracellular and nuclear PD-L1 in modulating cancer immunotherapy

Wenjun Xiong,Yang Gao,Wenyi Wei,Jinfang Zhang

DOI: https://doi.org/10.1016/j.trecan.2021.03.003

IF: 19.161

2021-09-01

Trends in Cancer

Abstract:Although targeting programmed death 1/programmed death ligand 1 (PD-1/PD-L1) has achieved durable responses and disease remission in patients with certain cancers, relatively low response rates and emerging resistance limit its clinical application. Hence, a more thorough understanding of regulatory mechanisms of the PD-1/PD-L1 axis is vital for developing combined therapeutic strategies to overcome hurdles of PD-1/PD-L1 blockade. Increasing evidence has demonstrated that PD-L1 can be secreted into the extracellular space or translocated into the nucleus, which also plays a critical role in regulating cancer immune evasion, tumorigenesis, and immunotherapy. In this review, we summarize these emerging roles of extracellular and nuclear PD-L1 and discuss future research directions and potential opportunities in translational medicine.

oncology
Regulation of PD-L1 expression in the tumor microenvironment

Ming Yi,Mengke Niu,Linping Xu,Suxia Luo,Kongming Wu

DOI: https://doi.org/10.1186/s13045-020-01027-5

2021-01-07

Abstract:Abstract Programmed death-ligand 1 (PD-L1) on cancer cells engages with programmed cell death-1 (PD-1) on immune cells, contributing to cancer immune escape. For multiple cancer types, the PD-1/PD-L1 axis is the major speed-limiting step of the anti-cancer immune response. In this context, blocking PD-1/PD-L1 could restore T cells from exhausted status and eradicate cancer cells. However, only a subset of PD-L1 positive patients benefits from α-PD-1/PD-L1 therapies. Actually, PD-L1 expression is regulated by various factors, leading to the diverse significances of PD-L1 positivity. Understanding the mechanisms of PD-L1 regulation is helpful to select patients and enhance the treatment effect. In this review, we focused on PD-L1 regulators at the levels of transcription, post-transcription, post-translation. Besides, we discussed the potential applications of these laboratory findings in the clinic.

oncology,hematology
Research update on PD-1/PD-L1 pathway in hematological diseases]

Yi Li,Jing Wang,Xiao-Yan Ke

DOI: https://doi.org/10.3969/j.issn.1672-4992.2020.16.038

2011-01-01

Abstract:Cross-priming is an important mechanism to activate immune response, which includes two classical signal pathways. Co-stimulatory signals are essential in the effective activation and B7-family is considered to be one of the most important factor in immunotherapy. PD-L1 is a new member of B7 family, whose ligand is PD-1. PD-1/PD-L1 can down-regulate the activation of immune response, which has become a focus of research. This article reviewed the expression of PD-1/PD-L1 in normal tissue and tumor, focusing on the status of PD-1/PD-L1 pathway study in leukemia, lymphoma, multiple myeloma, aplastic anemia and so on, in order to provide a new way for treatment of hematologic diseases.
William Lyell Ford 1936–1984

S. Fossum,B. Rolstad,M. Simonsen

DOI: https://doi.org/10.1111/j.1365-3083.1985.tb01433.x

1985-04-01

Scandinavian Journal of Immunology

Abstract:
Optimization of Cancer Immunotherapy on the Basis of Programmed Death Ligand‐1 Distribution and Function

Wei Zou,Xin Luo,Mengyuan Gao,Chang Yeon Yu,Xueting Wan,Suyun Yu,Yuanyuan Wu,Aiyun Wang,William Fenical,Zhonghong Wei,Yang Zhao,Yin Lu

DOI: https://doi.org/10.1111/bph.16054

IF: 7.3

2023-01-01

British Journal of Pharmacology

Abstract:Programmed cell death protein‐1 (PD‐1)/programmed death ligand‐1 (PD‐L1) immune checkpoint blockade as a breakthrough in cancer immunotherapy has shown unprecedented positive outcomes in the clinic. However, the overall effectiveness of PD‐L1 antibody is less than expected. An increasing number of studies have demonstrated that PD‐L1 is widely distributed and expressed not only on the cell membrane but also on the inside of the cells as well as on the extracellular vesicles secreted by tumour cells. Both endogenous and exogenous PD‐L1 play significant roles in influencing the therapeutic effect of anti‐tumour immunity. Herein, we mainly focused on the distribution and function of PD‐L1 and further summarized the potential targeted therapeutic strategies. More importantly, in addition to taking the overall expression abundance of PD‐L1 as a predictive indicator for selecting corresponding PD‐1/PD‐L1 monoclonal antibodies (mAbs), we also proposed that personalized combination therapies based on the different distribution of PD‐L1 are worth attention to achieve more efficient and effective therapeutic outcomes in cancer patients. LINKED ARTICLES This article is part of a themed issue on Cancer Microenvironment and Pharmacological Interventions. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v181.2/issuetoc
Fine pitch Cu pillar wafer process development and seed layer etching characterization

L. Siow,W. Deng,Qing Xin Zhang,T. Chai,C. G. Koh,D. Witarsa,Xianfeng Wang,Hongqi Sun,T. Ando,T. Y. Tee,J. Wong

DOI: https://doi.org/10.1109/EPTC.2012.6507185

2012-12-01

Abstract:This paper will revise the traditional wafer fabrication process flow to accommodate the new material used to achieve 40 um fine pitch Cu pillar with minimize seed layer undercut. New photo-resist material is introduced to attain a single coating of 40um thickness and it has demonstrated the capability of attaining an aspect ratio of 2. The wafer fabrication process ended using a combination of seed layer (Ti/Cu) wet and dry etching. It has shown the potential of achieving almost zero undercut which is very critical for a 20um via. Cross-sectional SEM will be carried out to verify the side wall profile and the footing of the photo-resist. FIB cross-section is done to identify Ti and Cu undercut. Bump shear test will be performed after the seed layer etching to quantify the failure mode of a bump with and without seed layer undercuts.

[Clinical analysis of lumbar spondylosis].

Progress of research on PD-1/PD-L1 in leukemia

Acute Myeloid Leukemia Cell-Intrinsic PD-1 Functions Promoting Leukemia Development by Recruiting SHP2

Targeting PD-1/PD-L1 pathway in myelodysplastic syndromes and acute myeloid leukemia

Strategies targeting PD-L1 expression and associated opportunities for cancer combination therapy

Emerging therapeutic frontiers in cancer: insights into posttranslational modifications of PD-1/PD-L1 and regulatory pathways

The progress and challenge of anti-PD-1/PD-L1 immunotherapy in treating non-small cell lung cancer

Recent progress, perspectives, and issues of engineered PD-L1 regulation nano-system to better cure tumor: A review

[Prevention of neuroses by timely heeding of complaints].

Various Uses of PD1/PD-L1 Inhibitor in Oncology: Opportunities and Challenges

The role of PD-1/PD-L1 and application of immune-checkpoint inhibitors in human cancers

PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations

PD-L1: From cancer immunotherapy to therapeutic implications in multiple disorders

PD-1/PD-L1 pathway: current researches in cancer.

PD-1 regulation in immune homeostasis and immunotherapy

Extracellular and nuclear PD-L1 in modulating cancer immunotherapy

Regulation of PD-L1 expression in the tumor microenvironment

Research update on PD-1/PD-L1 pathway in hematological diseases]

William Lyell Ford 1936–1984

Optimization of Cancer Immunotherapy on the Basis of Programmed Death Ligand‐1 Distribution and Function

Fine pitch Cu pillar wafer process development and seed layer etching characterization